Psoriasis Drug

Psoriasis Drug Market Outlook

The global psoriasis drug market is projected to reach USD 13.66 billion by 2035, expanding at a compound annual growth rate (CAGR) of approximately 9.4% during the forecast period from 2025 to 2035. This growth is primarily driven by the rising prevalence of psoriasis worldwide, along with increasing awareness regarding dermatological conditions and the availability of advanced therapeutic options. Additionally, the growing geriatric population, which is more susceptible to skin disorders, is also a significant contributing factor to the market expansion. Furthermore, the development of novel biologics and targeted therapies is expected to fuel market growth, as these drugs are designed to provide effective and tailored treatment solutions for patients suffering from various forms of psoriasis.

Growth Factor of the Market

The psoriasis drug market is bolstered by several growth factors that contribute to its robust expansion. First and foremost, the increasing prevalence of psoriasis, affecting approximately 2-3% of the global population, creates a sustained demand for effective treatments. Additionally, the rise of biologics and advanced therapies that target specific pathways in psoriasis pathology has revolutionized the treatment landscape, offering new hope for patients who have previously been unresponsive to traditional therapies. Moreover, heightened awareness and education regarding skin disorders play a crucial role in encouraging patients to seek medical consultation and treatment, thereby propelling market growth. Insurance coverage for dermatological treatments and an expanding range of product offerings across various types and applications further serve to enhance accessibility and affordability. Last but not least, ongoing research collaborations and investments in clinical trials aimed at discovering novel drug formulations are anticipated to provide additional momentum for the market in the coming years.

Key Highlights of the Market

• The global psoriasis drug market is projected to grow at a CAGR of 9.4% from 2025 to 2035.
• Biologics are expected to dominate the market, owing to their effectiveness and targeted action.
• North America holds the largest market share due to the high prevalence of psoriasis and advanced healthcare infrastructure.
• Online pharmacies are emerging as a significant channel for drug distribution, driven by convenience and accessibility.
• Growing geriatric population segments are likely to increase the incidence of psoriasis, further driving market growth.

By Product Type

Topical Psoriasis Drugs:

Topical psoriasis drugs remain a cornerstone in the management of this chronic condition, primarily due to their localized action and minimal systemic side effects. These formulations typically include corticosteroids, vitamin D analogs, and retinoids, which are applied directly to the affected skin areas. Topical treatments are often the first-line therapy for mild to moderate psoriasis and can be used in conjunction with other systemic treatments for enhanced efficacy. The accessibility and ease of use of topical medications contribute to their widespread adoption, making them a significant segment within the psoriasis drug market. Continuous research and development efforts aim to improve the formulation and absorption of these products, leading to better patient compliance and outcomes. The rising awareness of skin health and the importance of early intervention also bolster the demand for topical therapies.

Oral Psoriasis Drugs:

Oral psoriasis drugs have gained traction as an effective treatment option for patients with moderate to severe forms of the condition, particularly when topical therapies prove inadequate. These medications typically include methotrexate, cyclosporine, and apremilast, which act systemically to suppress the immune response that drives psoriasis. The appeal of oral drugs lies in their convenience, as they do not require the frequent application associated with topical treatments. Additionally, they offer strategic advantages in terms of managing widespread psoriasis. However, the potential for side effects and the necessity for regular monitoring can be drawbacks that healthcare providers consider when prescribing these therapies. The increasing prevalence of psoriasis and the need for more effective systemic treatments are expected to bolster the growth of the oral drug segment in the coming years.

Injectable Psoriasis Drugs:

Injectable psoriasis drugs, particularly biologic therapies, represent a revolutionary advancement in the treatment of psoriasis, particularly for patients with severe forms of the disease. These drugs, which include agents like adalimumab, etanercept, and ustekinumab, target specific immune pathways involved in inflammation and skin cell proliferation, leading to substantial improvements in symptoms and quality of life. The precision and effectiveness of injectable biologics make them a preferred choice among dermatologists for managing difficult cases of psoriasis. The growing body of clinical evidence supporting the efficacy of these drugs, coupled with the development of newer agents, is likely to drive significant growth in this segment. However, challenges such as high treatment costs and the need for ongoing patient education regarding self-administration could influence market dynamics.

Biologics for Psoriasis:

Biologics for psoriasis have emerged as a game-changer in the therapeutic landscape, offering targeted treatment options that specifically address the underlying mechanisms of the disease. These medications are derived from living organisms and are designed to inhibit certain immune responses that trigger psoriasis flare-ups. Due to their precision in targeting specific pathways, biologics often result in faster and more significant improvements in skin condition compared to traditional therapies. The increasing number of clinical trials demonstrating the safety and efficacy of various biologics is further solidifying their role in psoriasis treatment. The market for biologics is expected to expand substantially as more options become available, including new entrants that promise enhanced efficacy and safety profiles. Additionally, the establishment of comprehensive care programs for patients receiving biologic therapies is anticipated to improve adherence and outcomes.

By Application

Plaque Psoriasis:

Plaque psoriasis is the most common form of the disease, characterized by raised, red patches covered with silvery scales. This type accounts for approximately 80% of all psoriasis cases, making it a major focus in treatment development. The availability of various therapeutic options, including topical, oral, and biologic treatments, allows for tailored approaches to management based on the severity and extent of the lesions. The growing understanding of the inflammatory pathways involved in plaque psoriasis is driving research and innovation, leading to newer and more effective therapies. As healthcare providers increasingly recognize the importance of personalized treatment plans, the market for plaque psoriasis therapies is expected to maintain robust growth over the forecast period.

Guttate Psoriasis:

Guttate psoriasis, characterized by small, drop-shaped lesions, often arises after a streptococcal infection and is more common in younger patients. While this form of psoriasis can be self-limiting, it may require treatment to alleviate symptoms, particularly if it becomes chronic. Current treatment options include topical corticosteroids, phototherapy, and systemic medications. The unique nature of guttate psoriasis requires targeted therapies that address both the immune response and any underlying infections. As awareness of this condition increases and more patients seek effective treatments, the market for guttate psoriasis therapies is likely to expand, particularly in regions with high incidences of streptococcal infections.

Inverse Psoriasis:

Inverse psoriasis typically presents as smooth, inflamed patches in skin folds, such as the armpits, groin, and under the breasts. This form of psoriasis can be challenging to treat due to the sensitive nature of the affected skin and the potential for secondary infections. Treatment options often involve topical therapies that minimize irritation and promote healing while avoiding exacerbation of symptoms. The distinct characteristics of inverse psoriasis necessitate a focus on suitable treatments that effectively manage inflammation without compromising skin barrier function. As dermatological research continues to evolve, there is a growing emphasis on developing tailored therapies for this specific application, which is expected to fuel market growth.

Pustular Psoriasis:

Pustular psoriasis is characterized by the presence of white pustules (blisters of noninfectious pus) surrounded by red skin. This severe form of psoriasis can be debilitating and may require immediate medical intervention. Treatment options include systemic therapies, biologics, and topical agents that address both the immune system and the skin's inflammatory response. The complexity of managing pustular psoriasis often leads to a multidisciplinary approach involving dermatologists, rheumatologists, and primary care providers. The increasing recognition of the severe impact of this condition on patients’ lives is driving demand for effective therapies, positioning pustular psoriasis as a significant area of focus within the psoriasis drug market.

Erythrodermic Psoriasis:

Erythrodermic psoriasis is a rare but life-threatening form of psoriasis that can cover the entire body with a red, peeling rash that can itch or burn intensely. The urgency of treating erythrodermic psoriasis stems from potential complications, including severe skin infection and fluid loss. Currently, treatment strategies often involve systemic medications such as methotrexate, cyclosporine, or biologics, which require careful monitoring and management. The limited prevalence of this condition presents unique challenges in the market, as it necessitates highly specialized care and advanced therapeutic options. The ongoing research into erythrodermic psoriasis is expected to enhance understanding and ultimately improve treatment outcomes, contributing to market growth.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies are critical distribution channels for psoriasis drugs, particularly for patients requiring specialized care and access to advanced therapies such as biologics. These pharmacies ensure that patients receive medications that are appropriate for their specific conditions, often in conjunction with comprehensive care provided by healthcare teams. The ability to obtain consultations and support from medical professionals within the hospital setting adds significant value, particularly for those with severe or complex cases of psoriasis. The growing emphasis on integrated healthcare models and personalized treatment plans is likely to strengthen the role of hospital pharmacies in the psoriasis drug market.

Retail Pharmacies:

Retail pharmacies serve as a primary point of access for patients seeking psoriasis treatments, particularly for topical and over-the-counter options. The convenience and familiarity of retail pharmacies make them a preferred choice for patients managing mild to moderate psoriasis. These pharmacies often provide counseling and guidance on product selection, which can enhance adherence to treatment regimens. The expansion of retail pharmacy chains and the development of dedicated dermatology sections contribute to the accessibility of psoriasis medications. As public awareness of skin health increases, the retail pharmacy channel is expected to play a dynamic role in the growth of the psoriasis drug market.

Online Pharmacies:

The rise of online pharmacies offers a convenient alternative for patients seeking psoriasis medications, especially amid the increasing trend toward digital healthcare solutions. Online pharmacies provide a range of psoriasis treatment options, including both prescription and over-the-counter products, allowing patients to access medications from the comfort of their homes. The ease of ordering and the availability of discreet delivery options can encourage adherence to treatment plans, particularly for sensitive conditions such as psoriasis. However, the online pharmacy segment also faces challenges, including regulatory scrutiny and the need for robust patient education to ensure safe and appropriate medication use. As patient preferences shift toward online shopping, this channel is poised for significant growth in the psoriasis drug market.

By Ingredient Type

Corticosteroids:

Corticosteroids are one of the most widely used treatment options for psoriasis due to their potent anti-inflammatory effects. These agents work by reducing swelling, redness, and itching, making them a staple in topical therapies for both mild and moderate cases. The availability of a range of corticosteroid formulations—ranging from low to high potency—allows healthcare providers to tailor treatment according to the severity and location of psoriasis lesions. The relative affordability and established efficacy of corticosteroids continue to drive their utilization in the psoriasis drug market. Ongoing research is focused on improving the safety profile of these treatments to mitigate potential side effects associated with prolonged use.

Retinoids:

Retinoids, derivatives of vitamin A, play a pivotal role in the management of psoriasis, particularly in topical and systemic formulations. These agents work by regulating cell growth and differentiation, thereby reducing the rapid proliferation of skin cells characteristic of the condition. Combining retinoids with other therapies can enhance treatment outcomes, particularly in cases where traditional therapies have failed. The development of new retinoid compounds with improved efficacy and reduced side effects is ongoing. As patients and healthcare providers seek safer and more effective treatment options, retinoids are expected to maintain a significant presence in the psoriasis drug market.

Calcineurin Inhibitors:

Calcineurin inhibitors, such as tacrolimus and pimecrolimus, provide an alternative therapeutic option for psoriasis, particularly in sensitive areas such as the face and skin folds. Unlike corticosteroids, these agents do not carry the same risk of skin thinning, making them suitable for long-term use. Their mechanism of action involves the inhibition of T-cell activation and subsequent inflammatory response, effectively managing psoriasis lesions. The growing recognition of the importance of maintaining skin barrier function in psoriasis treatment is driving interest in calcineurin inhibitors. As awareness of their benefits increases, this ingredient type is expected to gain traction in the psoriasis drug market.

Biologics:

Biologics have revolutionized the treatment landscape for psoriasis, offering targeted therapies that address specific immune pathways involved in the disease. These advanced treatments are typically administered via injection and are particularly effective for moderate to severe cases of psoriasis. The development of multiple biologic agents has expanded treatment options, providing patients with tailored solutions that can lead to significant improvements in quality of life. The ongoing research and clinical trials dedicated to biologic therapies are expected to yield new products and combinations that enhance treatment efficacy. As the demand for personalized medicine grows, the biologics segment is anticipated to experience substantial growth in the psoriasis drug market.

By Region

North America is currently the largest market for psoriasis drugs, accounting for a significant share of the overall market revenue. The high prevalence of psoriasis in this region, coupled with well-established healthcare infrastructure and access to innovative treatment options, drives the demand for effective therapies. The market in North America is projected to grow at a CAGR of approximately 8.7% during the forecast period, fueled by the increasing adoption of biologics and advancements in drug formulations. Additionally, the presence of key pharmaceutical companies and ongoing clinical research contribute to North America's leadership in the psoriasis drug market.

Europe also exhibits a strong presence in the psoriasis drug market, driven by similar factors that influence North America. The region has witnessed a rising awareness of psoriasis and its impact on quality of life, leading to increased healthcare investments and improved patient access to treatments. Furthermore, the growing incidence of psoriasis in European populations, coupled with a strong focus on dermatological research and innovations, positions Europe as a key player in this market. The expansion of retail and online pharmacy channels in Europe further enhances the accessibility of psoriasis drugs, supporting market growth in the region. Overall, the competitive landscape in Europe is anticipated to develop significantly, contributing to the global psoriasis drug market.

Opportunities

The psoriasis drug market is ripe with opportunities that can significantly enhance growth prospects for stakeholders involved in the development and distribution of therapeutic solutions. One of the most promising opportunities lies in the continued research and development of biologics and targeted therapies, which are becoming increasingly popular for treating moderate to severe psoriasis. As the understanding of psoriasis pathology evolves, there is potential for the introduction of innovative treatment regimens that offer patients improved efficacy with minimized side effects. Furthermore, the expansion of telemedicine services has opened new avenues for patient engagement, facilitating easier access to specialized dermatological care and prescription medications. Moreover, geographical expansion into emerging markets, where awareness of psoriasis and its treatments is growing, presents lucrative opportunities for pharmaceutical companies looking to establish a foothold in new regions.

Another considerable opportunity comes from the increasing emphasis on personalized medicine, wherein treatment approaches are tailored to individual patients based on their specific disease profiles and responses to previous therapies. By focusing on patient-centric approaches, companies can enhance treatment adherence and overall satisfaction. Additionally, collaboration between pharmaceutical companies and research institutions aimed at accelerating clinical trials for new treatment options can lead to faster market entry of innovative therapies. The growing inclination among patients toward holistic treatment strategies, including lifestyle modification and adjunct therapies, also represents an opportunity for integrated care models that can improve patient outcomes and adherence to treatment. Ultimately, these diverse opportunities are set to drive noteworthy advancements in the psoriasis drug market.

Threats

While the psoriasis drug market showcases robust growth potential, it is not without its threats that could impact its trajectory. One significant threat arises from the high costs associated with advanced therapies, particularly biologics, which can limit patient access and adherence. Insurance coverage variations and the financial burden of treatment can deter many patients from pursuing necessary interventions, leading to suboptimal health outcomes. Additionally, the presence of alternative therapies and over-the-counter solutions may divert patients from prescribed treatments, further complicating the market landscape. Moreover, the rapid evolution of treatment modalities demands continuous innovation from pharmaceutical companies, creating pressure to keep pace with competitors' advancements. Regulatory hurdles and stringent approval processes for new drugs can also prolong time to market, potentially impacting revenue streams.

Another factor that poses a restraining threat to the market is the issue of drug safety and potential adverse effects associated with long-term use of certain psoriasis treatments. Increasing scrutiny from regulatory bodies regarding the safety profiles of existing drugs may prompt reevaluation and restrictions on their use. The emergence of counterfeit medications in the market also raises concerns about patient safety and can damage brand reputations. Additionally, the growing trend toward patient empowerment and self-management could lead to a decrease in traditional prescription-based treatment approaches. As patients become more informed about their condition and available therapies, there may be a shift toward alternative treatment pathways that could jeopardize the market for established psoriasis drugs.

Competitor Outlook

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson
• Novartis AG
• Regeneron Pharmaceuticals Inc.
• Roche Holding AG
• Merck & Co., Inc.
• Celgene Corporation
• Lilly USA, LLC
• GSK plc
• Sandoz International GmbH
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Dermira, Inc.
• UCB S.A.

The competitive landscape of the psoriasis drug market is characterized by a diverse array of key players that are actively engaged in the development, manufacturing, and marketing of innovative therapeutic solutions. Leading companies such as AbbVie and Amgen have established themselves as frontrunners through their respective biologic therapies, which have garnered widespread acceptance and adoption within the treatment community. With significant investment in research and development, these companies aim to expand their product portfolios and enhance the efficacy and safety of their offerings. The competitive dynamics are further influenced by the entry of new players and the emergence of novel therapeutic agents, which heightens the stakes for existing market leaders. As companies vie for market share, strategic collaborations, partnerships, and mergers and acquisitions are expected to play a pivotal role in shaping the competitive landscape.

AbbVie Inc. stands out as a prominent player in the psoriasis drug market, particularly known for its flagship biologic, Humira, which has set benchmarks for efficacy in treating moderate to severe psoriasis. The company's commitment to ongoing research has positioned it to introduce new formulations and combination therapies aimed at improving patient outcomes. Similarly, Amgen Inc. has successfully launched innovative therapies such as Otezla, which has broadened the treatment options for patients with moderate to severe psoriasis. With a strong emphasis on patient-centric approaches, Amgen continues to explore ways to enhance adherence and satisfaction through improved drug delivery methods. Meanwhile, Novartis AG is making significant strides with its biologic therapies, focusing on leveraging cutting-edge technologies to develop effective solutions tailored to individual patient needs.

Other notable players, such as Johnson & Johnson and Pfizer Inc., are also making substantial contributions to the psoriasis drug market, with their diverse portfolios encompassing both traditional and novel treatment options. Johnson & Johnson's innovative approach to drug development, coupled with its global reach, allows it to effectively cater to the varied needs of patients across different markets. On the other hand, Pfizer's commitment to advancing research in dermatology has positioned it as a key player in the competitive landscape. As the psoriasis drug market continues to evolve, these companies are expected to capitalize on emerging trends, including the shift towards personalized medicine and integrated care models, further solidifying their positions in the industry.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 GSK plc
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 UCB S.A.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Amgen Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 AbbVie Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Pfizer Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Dermira, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Lilly USA, LLC
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Roche Holding AG
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Johnson & Johnson
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Merck & Co., Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Celgene Corporation
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Sandoz International GmbH
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Bristol-Myers Squibb Company
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Regeneron Pharmaceuticals Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Psoriasis Drug Market, By Application
    • 6.1.1 Plaque Psoriasis
    • 6.1.2 Guttate Psoriasis
    • 6.1.3 Inverse Psoriasis
    • 6.1.4 Pustular Psoriasis
    • 6.1.5 Erythrodermic Psoriasis
  • 6.2 Psoriasis Drug Market, By Product Type
    • 6.2.1 Topical Psoriasis Drugs
    • 6.2.2 Oral Psoriasis Drugs
    • 6.2.3 Injectable Psoriasis Drugs
    • 6.2.4 Biologics for Psoriasis
  • 6.3 Psoriasis Drug Market, By Ingredient Type
    • 6.3.1 Corticosteroids
    • 6.3.2 Retinoids
    • 6.3.3 Calcineurin Inhibitors
    • 6.3.4 Biologics
  • 6.4 Psoriasis Drug Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Psoriasis Drug Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Psoriasis Drug market is categorized based on

By Product Type

• Topical Psoriasis Drugs
• Oral Psoriasis Drugs
• Injectable Psoriasis Drugs
• Biologics for Psoriasis

By Application

• Plaque Psoriasis
• Guttate Psoriasis
• Inverse Psoriasis
• Pustular Psoriasis
• Erythrodermic Psoriasis

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Corticosteroids
• Retinoids
• Calcineurin Inhibitors
• Biologics

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson
• Novartis AG
• Regeneron Pharmaceuticals Inc.
• Roche Holding AG
• Merck & Co., Inc.
• Celgene Corporation
• Lilly USA, LLC
• GSK plc
• Sandoz International GmbH
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Dermira, Inc.
• UCB S.A.